{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:09:55Z","timestamp":1789200595476,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020\u201000591"],"award-info":[{"award-number":["2020\u201000591"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Machine learning studies sometimes include a high number of predictors relative to the number of training cases. This increases the risk of overfitting and poor generalizability. A recent study hypothesized that between\u2010trial heterogeneity precluded generalizable outcome prediction in schizophrenia from being achieved. However, an alternative explanation is that predictor overinclusion might explain the low generalizability in that analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Positive and Negative Syndrome Scale (PANSS) item\u2010data, age, sex, and treatment allocation (antipsychotic\/placebo) from 18 placebo\u2010controlled trials of risperidone and paliperidone, in schizophrenia or schizoaffective disorder, were used as predictors for training five supervised learning models to predict symptom remission after 4\u2009weeks of treatment. Sensitivity analyses varying the number of training cases and including simulated uninformative predictors were conducted to assess model performance, as were analyses on simulated data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Better\u2010than\u2010chance predictions could be achieved for all models using as few as 384 training cases (BAC 0.60, SD 0.035 for an ensemble model). Model performance increased with the number of training cases (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094384, BAC 0.63, SD 0.041) and was higher when validated on a set of unseen trials without placebo controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091508, BAC 0.68, SD 0.013). Predictive performance was substantially decreased by including simulated uninformative predictors. Analyses of simulated data suggest that considerably larger sample sizes than commonly used might be required to effectively separate weakly informative from uninformative predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Supervised learning models can generate better\u2010than\u2010chance predictions in schizophrenia from small datasets, but this requires that not too many uninformative predictors are included. Since highly predictive models have not yet been established for schizophrenia\u2014and since strong linear predictors are easy to identify\u2014commonly collected clinical trial data likely do not contain predictors with strong linear relations to clinically relevant outcomes. If correct, future machine learning analyses should focus on maximizing the probability of identifying weakly predictive features.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/acps.70037","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:11:42Z","timestamp":1757506302000},"page":"441-450","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting Remission in Schizophrenia Using Machine Learning\u2014Assessing the Impact of Sample Size and Predictor Overinclusion"],"prefix":"10.1111","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0930-6068","authenticated-orcid":false,"given":"Fredrik","family":"Hieronymus","sequence":"first","affiliation":[{"name":"Institute of Neuroscience and Physiology University of Gothenburg  Gothenburg Sweden"},{"name":"Department of Clinical Medicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Hieronymus","sequence":"additional","affiliation":[{"name":"Swedish Meteorological and Hydrological Institute  Norrk\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Sj\u00f6stedt","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Institute of Laboratory Medicine University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"N\u00e4slund","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lisinski","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8032-6208","authenticated-orcid":false,"given":"S\u00f8ren Dinesen","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine Aarhus University  Aarhus Denmark"},{"name":"Department of Affective Disorders Aarhus University Hospital\u2014Psychiatry  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-021-10092-0"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3756"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500523"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.10.003"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01690-5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0607-2"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg8538"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patrec.2008.04.010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00357-019-09327-3"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsta.2009.0159"},{"key":"e_1_2_11_12_1","unstructured":"Yale University \u201cYale University Open Data Access Project \u201d2024 https:\/\/yoda.yale.edu\/."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_11_14_1","unstructured":"United States Food & Drug Administration \u201cDrug Approval Package\u2014Risperdal \u201d1993Available via request to the United States Food & Drug Administration or by contacting the authors."},{"key":"e_1_2_11_15_1","unstructured":"United States Food & Drug Administration \u201cDrug Approval Package\u2014Risperdal Supplemental Application for Schizophrenia in Adolescents \u201d2007 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/020272Orig1s046\u2010part1.pdf."},{"key":"e_1_2_11_16_1","unstructured":"United States Food & Drug Administration \u201cDrug Approval Package\u2014Risperdal Supplemental Application for Once\u2010Daily Dosing \u201d1997 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/20588.pdf."},{"key":"e_1_2_11_17_1","unstructured":"United States Food & Drug Administration \u201cDrug Approval Package\u2014Risperdal Consta \u201d2003 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21346_Risperdal%20Consta%20Long\u2010Acting%20Injection_medr.PDF."},{"key":"e_1_2_11_18_1","unstructured":"United States Food & Drug Administration \u201cDrug Approval Package\u2014Invega \u201d2006 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021999s000_TOC.cfm."},{"key":"e_1_2_11_19_1","unstructured":"United States Food & Drug Administration \u201cClinical Review\u2014Invega Adolescents \u201d2011 https:\/\/www.fda.gov\/media\/80425\/download."},{"key":"e_1_2_11_20_1","unstructured":"United States Food & Drug Administration \u201cMedical Review\u2014Invega Sustenna \u201d2009 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022264s000medr.pdf."},{"key":"e_1_2_11_21_1","unstructured":"European Medicines Agency \u201cAssessment Report\u2014Invega Schizoaffective Disorder \u201d2010 https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/invega\u2010h\u2010c\u2010746\u2010ii\u20100023\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf."},{"key":"e_1_2_11_22_1","unstructured":"Janssen Pharmaceutical K.K \u201cClinical Study Report\u2014PALM\u2010JPN\u20104 (NCT01299389) \u201d2013 https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01299389."},{"key":"e_1_2_11_23_1","unstructured":"Johnson & Johnson Pharmaceutical Research & Development LLC \u201cClinical Study Report\u2014R076477\u2010SCH\u20104012 (NCT00524043) \u201d2014 https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00524043."},{"key":"e_1_2_11_24_1","unstructured":"Johnson & Johnson Pharmaceutical Research & Development LLC \u201cClinical Study Report\u2014R076477\u2010SCH\u20103015 (NCT00334126) \u201d2014 https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00334126."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02491-6"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00168-x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.441"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.962"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12021-013-9204-3"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1109\/MIPRO.2015.7160458"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111379"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.048"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1605348"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1713258"},{"key":"e_1_2_11_37_1","unstructured":"National Institutes of Mental Health Repository & Genomics Resource \u201cDownload data\u2014Schizophrenia \u201d2024 https:\/\/www.nimhgenetics.org\/download\u2010tool\/SZ."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0301"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.01.018"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-02060-x"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.70037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:02:47Z","timestamp":1762408967000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.70037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/acps.70037"],"URL":"https:\/\/doi.org\/10.1111\/acps.70037","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/ACPS.70037\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.70037\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"2025-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}